Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
Acta Pharmacologica Sinica, Published online: 03 January 2024; doi:10.1038/s41401-023-01217-0Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - January 3, 2024 Category: Drugs & Pharmacology Authors: Xiao-xue Li Zheng-dong Chen Xue-jiao Sun Yi-qing Yang Hong Jin Nai-feng Liu Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.PMID:38110583 | DOI:10.1038/s41401-023-01192-6 (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Meng-Yang Wang Tian-Xiang Yu Qin-Yan Wang Xue Han Xiang Hu Shi-Ju Ye Xiao-Hong Long Yi Wang Hong Zhu Wu Luo Guang Liang Source Type: research
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Acta Pharmacol Sin. 2023 Dec 19. doi: 10.1038/s41401-023-01205-4. Online ahead of print.ABSTRACTOsimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanisms of Osi resistance remain largely unexplored, and efficient strategies to reverse the resistance are urgently needed. Here, we developed a lactoferrin-modified liposomal codelivery system for the combination therapy of Osi and panobinostat (Pan), an epigenetic regulator of histone acetylation. We demonstrated that ...
Source: Acta Pharmacologica Sinica - December 19, 2023 Category: Drugs & Pharmacology Authors: Ting-Ting Lin Wei Xiong Gui-Hua Chen Yang He Li Long Xin-Fu Gao Jia-Lin Zhou Wen-Wen Lv Yong-Zhuo Huang Source Type: research
